Baxiva is an ETH Zurich spin-off building next-generation glycoconjugate vaccines to prevent serious infections caused by Gram-negative bacteria, starting with extraintestinal pathogenic E. coli (ExPEC) - the leading cause of UTIs and a major driver of sepsis and antimicrobial resistance. With no approved ExPEC vaccine, prevention represents a large, underserved market. Baxiva’s proprietary conjugation platform links bacterial surface polysaccharides to highly immunogenic nanoparticle carriers to enable scalable, multivalent vaccines. The company is supported by CARB-X and is building a partner-oriented path to market through co-development or licensing with global vaccine manufacturers.
News
Milestones/News
